PMI-5011

PMI-5011 is an ethanolic extract of the plant Artemisia dracunculus L. (also known as Russian tarragon). It is a botanical drug candidate studied primarily for its potential to improve insulin sensitivity and modulate glucose metabolism. Mechanistic studies indicate that PMI-5011 enhances insulin secretion from pancreatic beta cells, maintains beta cell number, and promotes insulin release via activation of AMP-activated protein kinase (AMPK) and protein kinase B (Akt/PKB). It suppresses inflammatory responses in macrophages by inhibiting inducible nitric oxide synthase (iNOS), nitric oxide production, and pro-inflammatory cytokines such as IL-6. In skeletal muscle, PMI-5011 augments insulin signaling by increasing PI3K activity, enhancing Akt phosphorylation, decreasing activity and expression of protein tyrosine phosphatase 1B (PTP1B), and downregulating ubiquitin-proteasome pathway regulators Atrogin-1 and MuRF-1. These actions collectively contribute to improved insulin sensitivity, glycogen synthesis, and resistance to insulin resistance induced by fatty acids or inflammatory stimuli. PMI-5011 is being investigated as a novel therapeutic approach for Type 2 Diabetes but remains a research compound without regulatory approval for use as a drug[1][2][3][4][5].

Other names

Artemisia dracunculus L. extractRussian tarragon extract